EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides

Stefanie Porkert, Johannes Griss, Mercedes Hudelist-Venz, Irene Steiner, Julia Valencak, Wolfgang Weninger, Patrick M Brunner, Constanze Jonak

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024

DOI: 10.1111/ddg.15331 ↗

At a glance

Journal article in JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Written by Stefanie Porkert and 7 co-authors. Institution: Department of Dermatology, Medical University of Vienna, Viena, Austria. Major MEDLINE topics: Mycosis Fungoides, Skin Neoplasms. Cited 2 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Objectives Mycosis fungoides (MF), the most common primary cutaneous T‐cell lymphoma, is characterized by a variable clinical course, presenting either as indolent disease or showing fatal progression due to extracutaneous involvement. Importantly, the lack of prognostic models and predominantly palliative therapy settings hamper patient care. Here, we aimed to define survival rates, disease prediction accuracy, and treatment impact in MF. Patients and methods Hundred‐forty MF patients were assessed retrospectively. Prognosis and disease progression/survival were analyzed using univariate Cox proportional hazards regression model and Kaplan‐Meier estimates.

Results

Skin tumors were linked to shorter progression‐free, overall survival and a 3.48 increased risk for disease progression when compared to erythroderma. The Cutaneous Lymphoma International Prognostic Index identified patients at risk in early‐stage disease only. Moreover, expression of Ki‐67 >20%, CD30 >10%, CD20 + , and CD7 – were associated with a significantly worse outcome independent of disease stage. Only single‐agent interferon‐α and phototherapy combined with interferon‐α or retinoids/bexarotene achieved long‐term disease control in MF.

Conclusions

Our data support predictive validity of prognostic factors and models in MF and identified further potential parameters associated with poor survival. Prospective studies on prognostic indices across disease stages and treatment modalities are needed to predict and improve survival.

Subjects

MeSH terms (MEDLINE)

Mycosis FungoidesSkin NeoplasmsHumansPrognosisRetrospective StudiesProspective StudiesTreatment OutcomeInterferon-alphaDisease ProgressionNeoplasm Staging

Author keywords

Mycosis fungoidesTTNTcutaneous T‐cell lymphomamortalityprognostic models

Substances

Interferon-alpha

Authors and institutions

  • Department of Dermatology, Medical University of Vienna, Viena, Austria.
  • Department of Radiotherapy and Radiobiology, Medical University of Vienna, Viena, Austria.
  • Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, Viena, Austria.
  • Department of Dermatology, Icahn School of Medicineat Mount Sinai, New York, NY, USA.

Cite

APA

Porkert, S., Griss, J., Hudelist-Venz, M., Steiner, I., Valencak, J., Weninger, W., Brunner, P. M., & Jonak, C. (2024). Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15331

Vancouver

Porkert S, Griss J, Hudelist-Venz M, Steiner I, Valencak J, Weninger W, et al. Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15331

BibTeX
@article{Porkert2024,
  author = {Porkert, Stefanie and Griss, Johannes and Hudelist-Venz, Mercedes and Steiner, Irene and Valencak, Julia and Weninger, Wolfgang and Brunner, Patrick M and Jonak, Constanze},
  title = {Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2024},
  doi = {10.1111/ddg.15331}
}
Start for free →